Accelerate Diagnostics Announces Launch of Proposed Public Offering

TUCSON, Ariz., Jan. 16, 2024 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the “Company”) today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock and/or additional warrants to purchase up to 675,000 shares of common stock, in any combination thereof, at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

Read more at prnewswire.com